NOVAST Laboratories, Limited (SHE:301569)

NOVAST Laboratories Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 29, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Debt / Equity Ratio	-0.62	-0.60	-0.56	-0.53	-0.53	-0.23
Net Debt / EBITDA Ratio	-3.60	-4.28	-3.70	-6.70	-9.95	-1.46
Net Debt / FCF Ratio	-4.45	-4.85	-6.26	-10.93	-5.05	-1.57
Asset Turnover	-	0.41	0.46	0.43	0.40	0.61
Inventory Turnover	-	1.88	1.68	1.41	1.24	1.57
Quick Ratio	11.54	8.25	7.03	8.24	9.38	2.68
Current Ratio	13.38	9.71	8.64	10.94	13.13	3.73
Return on Equity (ROE)	-	11.99%	15.69%	8.12%	10.20%	10.72%
Return on Assets (ROA)	-	7.04%	7.83%	3.30%	1.75%	6.38%
Return on Invested Capital (ROIC)	36.07%	26.61%	28.52%	11.00%	5.05%	14.22%
Return on Capital Employed (ROCE)	14.80%	11.50%	12.60%	5.30%	2.60%	11.10%

Yields

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 29, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Payout Ratio	-	29.85%	-	-	-	59.08%
Buyback Yield / Dilution	-0.20%	-	-	-0.60%	-26.11%	-3.10%

Data Source: S&P Global Market Intelligence Last updated: Oct 29, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 30, 2026

Data Sources Report a data error